CIDP Standard of Care Treatment Options and Immunoglobulin Dosing: Insights from the ICE Trial

This episode, titled "CIDP Standard of Care Treatment Options and Immunoglobulin Dosing: Insights from the ICE Trial," features panelists reviewing the current landscape of guideline-supported treatments for CIDP and examining how clinical decision-making shapes therapy selection for individual patients. The discussion opens with an overview of available treatment options, including corticosteroids administered intravenously or orally, IVIG, subcutaneous immunoglobulin, efgartigimod, and plasmapheresis. Panelists note the longstanding role of corticosteroids while acknowledging growing awareness of their toxicity risks with long-term use and the potential for worsening in motor CIDP and multifocal presentations. Patient comorbidities, particularly diabetes, are identified as a key factor in steering treatment selection away from steroids and toward immunoglobulin products. When monotherapy proves insufficient, panelists describe a practice of combining IVIG with steroids or adding long-term immunosuppressants such as azathioprine or mycophenolate, though the evidence base for the latter remains limited.

The conversation then focuses on immunoglobulin therapy, which carries the strongest evidentiary support among available treatments. Panelists review the pivotal ICE study, published in 2008, which demonstrated that approximately 45% of patients achieved a meaningful improvement in disability scores, and that over 80% of responders remained stable over 48 weeks in the extension phase. This study established the standard dosing protocol of a 2 g/kg induction dose followed by 1 g/kg every three weeks. Panelists further discuss a 2022 dose-response study published in Brain, which demonstrated that higher maintenance doses were associated with lower relapse rates, providing clinicians with evidence to support individualized dosing adjustments. The panel agrees that while 1 g/kg every three weeks serves as a practical starting point, dosing frequency and amount should be tailored to each patient's clinical response, with some patients requiring more frequent infusions or higher doses to maintain stability.

In the next episode, "Real-World Evidence for Immunoglobulin Therapy in CIDP," panelists will examine real-world data supporting the use of immunoglobulin therapy in CIDP, highlighting findings from a large claims-based study demonstrating a 40% reduction in progressive disability among immunoglobulin-treated patients, as well as evidence suggesting that immunoglobulin therapy may also reduce pain-related medication use.